{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":25,"podcast":6,"youtube":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05933577\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05933577","nct_id":"NCT05933577","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05933577. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.","label":"Intismeran autogene + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.","label":"Placebo + Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2030-09-26","type":"ESTIMATED"},"conditions":["Melanoma"],"enrollment":{"count":1089,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran autogene","type":"BIOLOGICAL"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"OTHER"}],"last_update":"2025-09-24","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-10-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS)","timeFrame":"Up to approximately 74 months"}],"references":[],"start_date":{"date":"2023-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)","url":"https://clinicaltrials.gov/study/NCT05933577"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05933577"}